title: Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension.
abstract: The 24-h blood pressure control of bisoprolol, a new beta-selective, beta-blocking agent, was studied in 240 mild to moderate hypertensive patients in this 4-week, randomized, double-blind, placebo-controlled trial. A once-daily dosing schedule was evaluated by comparing bisoprolol's antihypertensive effectivness and safety at 24 h postdose and 3 h postdose, the latter time intended to correspond to peak effectiveness. Results from this trial demonstrated the antihypertensive effectiveness of once-daily bisprolol at doses ranging from 5-20 mg. Mean reductions from baseline diastolic blood pressure, measured 24 h postdose, were 6.3, 8.8, and 10.1 mmHg for patients receiving bisoprolol 5, 10, and 20 mg, respectively, compared with 1.6 mmHg for placebo-treated patients (p < 0.01); mean reductions from baseline systolic blood pressure for the bisoprolol groups were 8.6, 8.6, and 10.9 mmHg, respectively, versus 3.3 mmHg for placebo (p < or = 0.01); and mean reductions from baseline heart rate for the bisoprolol groups were 5.1, 7.1, and 10.2 beats/min, respectively, compared with a 0.9 beats/min increase in heart rate for the placebo group (p < 0.01). The response rates for bisoprolol-treated patients ranged from 47 to 70% compared with 18% for patients on placebo (p < 0.01). Antihypertensive effects were dose-related and sustained over the 24-h dosing interval. Near maximal antihypertensive effects were achieved within 1 week of initiation of therapy with bisoprolol and were sustained over the course of the trial.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Georgetown University School of Medicine, Washington, DC.
authors.forename: M E
authors.initials: ME
authors.lastname: Davidov
authors.forename: S P
authors.initials: SP
authors.lastname: Singh
authors.forename: N D
authors.initials: ND
authors.lastname: Vlachakis
authors.forename: J B
authors.initials: JB
authors.lastname: Blumenthal
authors.forename: J S
authors.initials: JS
authors.lastname: Simon
authors.forename: B S
authors.initials: BS
authors.lastname: Bryzinski
authors.forename: K J
authors.initials: KJ
authors.lastname: Koury
authors.forename: D
authors.initials: D
authors.lastname: Alemayehu
mesh_terms: D000328:Adult; D017298:Bisoprolol / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010352:Patient Dropouts; D010919:Placebos; D012449:Safety; D016037:Single-Blind Method; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D017298:Bisoprolol